STING Signaling Modulation via Negative Regulator Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating STING signaling in cancer therapy are limited by the risk of immunosuppressive effects and lack of therapeutic agents that effectively enhance STING activity without causing autoimmunity, as STING activation can lead to autoimmunity and impaired cancer immunity.
Innovation Solution
The disclosure provides compositions and methods for enhancing STING activity by inhibiting negative regulators such as ESCRT and DNAJC13, which negatively regulate STING signaling, thereby augmenting innate immune responses and cancer immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If STING activation is enhanced to improve cancer immunotherapy, then innate immune response is boosted, but risk of autoimmunity increases
Solution Approach 1:
The patent segments the STING signaling pathway regulation by specifically targeting negative regulators (DNAJC13, ESCRT complexes) rather than broadly activating STING. This selective inhibition allows enhancement of anti-tumor immune responses while preserving natural regulatory mechanisms that prevent autoimmunity.
Solution Approach 2:
The patent uses small molecule inhibitors as intermediaries to block negative regulators of STING signaling. These inhibitors (compounds of Formula I) act as mediators that indirectly enhance STING activity without directly overactivating the pathway, thereby reducing the risk of autoimmunity while maintaining cancer immunotherapy efficacy.
2Reliability
If negative regulators of STING are inhibited to enhance STING signaling, then innate immune response is augmented, but off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target negative regulators (DNAJC13, ESCRT-0, ESCRT-I, ESCRT-III) involved in STING degradation. This localized targeting ensures that only the specific regulatory nodes controlling STING stability are affected, minimizing off-target effects while achieving reliable STING signaling enhancement.
Solution Approach 2:
The patent changes the regulatory parameters of STING signaling by modulating the activity of negative regulators through small molecule inhibition. This parameter change approach allows fine-tuning of STING activity levels to achieve therapeutic enhancement without causing excessive activation or off-target effects.
3Reliability
If STING activity is increased to improve pathogen defense, then innate immune response is enhanced, but immunosuppressive effects may occur
Solution Approach 1:
The patent introduces dynamics to STING signaling regulation by reversibly inhibiting negative regulators with small molecule compounds. This dynamic modulation allows the system to respond appropriately to different threats while maintaining homeostasis, preventing both insufficient pathogen defense and excessive immunosuppression.
Solution Approach 2:
The patent leverages the natural feedback mechanisms of the STING pathway by selectively inhibiting negative regulators. The endogenous feedback loops continue to function, allowing the system to self-regulate and prevent immunosuppressive effects while maintaining enhanced pathogen defense capability.
Data Source
AI summary
Provided herein are compositions and methods for enhancing the activity of Stimulator of Interferon Genes (STING) with one or more agents for inhibiting the activity of one or more negative regulators of STING, including DNAJC13 and ESCRT.